

ARD-61 biochemical

ARD-61

CATALOG #
AAA228317

PRODUCT SYNONYMS

ARD-61; ARD-61 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2316837-08-6
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	ARD-61 (25, 50mg/kg/day; ip; for 75 days) effectively inhibits tumor growth in the MDA-MB-453 xenograft tumor model in male SCID mice[1]. ARD-61 (25mg/kg; ip; single dose) effectively and rapidly reduces the AR protein in the MDA-MB-453 xenograft tissue, with the effect persisting for at least 24h. ARD-61 is very effective in reducing the mRNA level of WNT7B in a time-dependent manner[1]. Animal Model: MDA-MB-453 xenograft tumor model in male SCID mice[1]. Dosage: 25, 50mg/kg. Administration: IP; daily; for 75 days. Result: Effectively inhibited tumor growth.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Anticancer agent 15, CAS 2710312-73-3



Structure
Anticancer agent 15, CAS 2710312-73-3

ADDITIONAL INFORMATION

Related Product Information for ARD-61 biochemical	ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice.
References	1. Zhang K, et al. A Novel Anticancer Stem Cell Compound Derived from Pleuromutilin Induced Necroptosis of Melanoma Cells. J Med Chem. 2021 Nov 11;64(21):15825-15845.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.